Key Points The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held before the filing. This capital commitment occurred as shares were priced at $114.34 at the September 8, 2026 market close, following a 293% total return over the preceding 12 months. 10 stocks we like better than Inhibrx Biosciences › Mark Lappe, Chief Executive Officer, purchased 25,000 shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) on September 8, 2026. SEC Form 4 filing . Transaction summary Transaction value based on SEC Form 4 weighted average purchase price ($105.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.